Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.